Fritextsökning
Innehållstyper
-
Anna Törner: To kill your darlings
Hopes were high when Anna Törner and her colleague started a study on a dietary supplement that seemed unbelievably good. “Enthusiastically, we dreamed of excit...
-
ALS – When the body has given up, but the brain persists
The nerve disease ALS gradually deprives the patient of control over the muscles and, eventually, also of speech. The eyes continue to function, though, and wit...
-
Marie Gårdmark: Do EMA and FDA talk to each other?
Of course they do! The collaboration started already in 2003, writes Marie Gårdmark in a column.
-
Samuel Lagercrantz: Immunotherapy against cancer is still in its early stages
For more than 100 years, researchers have tried to target the body’s own immune system to fight cancer cells. They have occasionally been laughed at and ridicul...
-
Marie Gårdmark: Potential step change – EU regulators get to play with data
A new pilot from EMA is starting in September to assess wether the analysis of 'raw data' by regulatory authorities improves the evaluation of marketing approva...
-
Marie Gårdmark: Finally, it’s time for a revision of the EU pharma legislation
A challenge for the EU Commission is to deliver a new framework that will also take care of another “pillar” of the pharmaceutical strategy, namely, to ensure t...
-
Lucy Robertshaw: Are we in the perfect storm?
“Is there a perfect storm on the horizon again as elective surgeries were cancelled due to patients being admitted with Covid-19? We now have a long backlog of ...
-
Giulia Gaudenzi: Innovation for good
"I challenge the innovator landscape to take a mental leap. Relying on innovation-solely to end inequality is not enough, therefore consciously and purposively ...
-
Samuel Lagercrantz: Collaboration and joint efforts are the key to success
Although many questions about Covid-19 remain unanswered, the development of drugs and vaccines has been incredibly rapid, writes Samuel Lagercrantz, Life Scien...
-
The perfect formula for decision-making
No one has the luxury not to take a decision, writes Helena Strigård at Swedenbio.
-
Giulia Gaudenzi: ”Key lessons from global health research”
The world will still face major challenges in the post Covid-19 pandemic, writes Giulia Gaudenzi at the KTH Division of Nanobiotechnology at Scilifelab, in a column.
-
Björn Arvidsson: ”We need to change perspective”
If you say “life science” to a person on the street and ask them to explain what it is, you will probably get no good answer. The same question to your network ...
-
Column: Why there cannot be a complete cure for cancer – but there is certainly another way!
"Is there a new way we need to be thinking about how to prevent cancer?" Lucy Robertshaw reflects upon which is the smartest way to beat cancer.
-
It´s time to establish relations
Communication with the patient is the key to future healthcare, writes Hanna Brodda, editor in chief of Life Science Sweden.
-
“Together Stockholm-Uppsala and Medicon Valley can make Scandinavia a leading life science region”
“Denmark, Sweden, Norway and Finland all have national life science strategies, but the Swedish strategy is the only one explicitly emphasizing the Nordic dimen...
-
Norway finds its path in life science
The life science sector in Norway is on the rise.
-
Eli Lilly writes biotech fine history
The American biotech company Eli Lilly will pay US 1.415 billion to resolve allegations of off-label promotion of a dementia drug.
-
SDU professor helps EU
Mette Præst Knudsen from the University of Southern Denmark, SDU, has been appointed as an expert member in an EU politics group.
BREAKING